Corpus ID: 78299102

Výsledky dlouhodobé klinické studie: prodloužení přežití u pacientů s metastatickým karcinomem prostaty léčených klodronátem

  title={V{\'y}sledky dlouhodob{\'e} klinick{\'e} studie: prodlou{\vz}en{\'i} pře{\vz}it{\'i} u pacientů s metastatick{\'y}m karcinomem prostaty l{\'e}{\vc}en{\'y}ch klodron{\'a}tem},
  author={Petr Bene{\vs}},
Bisfosfonaty jsou soucasti komplexni lecebne strategie u vsech onkologických diagnoz, ktere způsobuji nadorovou kostni chorobu. Bisfosfonaty se použivaji od 80. let minuleho stoleti a neustale maji pro pacienty velký přinos. Ve studii, ktera je zde prezentovana se hodnoti přinos prvni generace bisfosfonatů tj. klodronatu, nejen z hlediska jeho ucinku na kostni přihody, ale hodnoti se zde i výsledky dlouhodobeho přežiti pacientů. Data ve zmiňovane studii ukazuji, že u skupiny pacientů u… Expand


Oral sodium clodronate for nonmetastatic prostate cancer--results of a randomized double-blind placebo-controlled trial: Medical Research Council PR04 (ISRCTN61384873).
Adjuvant sodium clodronate does not modify the natural history of nonmetastatic prostate cancer, and the group allocated to each treatment were well balanced. Expand
Adjuvant bisphosphonates in breast cancer: are we witnessing the emergence of a new therapeutic strategy?
Clinical trial results with the early oral bisphosphonate and clodronate were judged to be inconclusive but the recent data with zoledronic acid suggest that bone targeted treatments may indeed modify the course of the disease. Expand
Use of zoledronate to treat osteoblastic versus osteolytic lesions in a severe-combined-immunodeficient mouse model.
Evaluating the efficacy of zoledronate in limiting the formation and/or progression of osteoblastic lesions produced by the injection of known prostate cancer cells into the tibia of SCID mice suggested that osteoclast activity may not be critical for the development of osteoclastic lesions associated with prostate tumor cells. Expand
The role of bisphosphonates in breast and prostate cancers.
Large, randomised, multicentre trials using intravenous administration of the highly potent bisphosphonate zoledronic acid every 3-4 weeks have recently demonstrated a reduction of 20% in the risk of developing an SRE compared with pamidronate for patients with breast cancer. Expand
Bisphosphonates in Bone Disease: From the Laboratory to the Patient
Bisphosphonates-Preclinical: Background to the pharmacological development: Chemistry and actions, and future prospects. Expand
Osteoprotegerin inhibits prostate cancer-induced osteoclastogenesis and prevents prostate tumor growth in the bone.
It is demonstrated that CaP cells directly induce osteoclastogenesis from osteocline precursors in the absence of underlying stroma in vitro, which emphasizes the important role that osteOClast activity plays in the establishment of CaP skeletal metastases, including those with an osteoblastic component. Expand
Generalised increase in bone resorption in carcinoma of the prostate.
It is suggested that prostatic cancer induces generalised loss of trabecular bone which may minimise disturbances in plasma calcium homeostasis but could contribute to morbidity. Expand
Podávání bisfosfonátů u pacientů s karcinomem prostaty metastazujícím do kostí
  • Farmakoterapie
  • 2007
Oral sodium clodronate for metastatic prostate cancer double-blind, placebocontrolled randomised trial: MRC PR05 (ISRCTN38477744)
  • J Natl Cancer Inst
  • 2003